MARKET

BVXV

BVXV

BiondVax
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.080
-0.030
-0.96%
Opening 11:29 12/02 EST
OPEN
3.160
PREV CLOSE
3.110
HIGH
3.160
LOW
3.000
VOLUME
134.17K
TURNOVER
--
52 WEEK HIGH
62.00
52 WEEK LOW
2.350
MARKET CAP
35.48M
P/E (TTM)
-1.0299
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 28)
Benzinga · 10/29 11:30
Energy Transfer, Teck Resources leads premarket losers' pack
Catabasis Pharmaceuticals (CATB) -64% after halting development of edasalonexent.Dragon Victory International (LYL) -17%.Sharps Compliance (SMED) -11% on FQ1 earning release.Liquid Media Group (YVR) -7%.BiondVax Pharmaceuticals (BVXV) -6%.Muscle Maker (GRIL) -6%.Teck Resources (TECK) -6% on Q3 earnings release.Energy
Seekingalpha · 10/27 12:26
SAP, DNKN, CODX and NNDM among midday movers
Gainers: Document Security Systems (DSS) +43%.Muscle Maker (GRIL) +39%.Lianluo Smart (LLIT) +35%.Co-Diagnostics (CODX) +19%.SilverSun Technologies (SSNT) +18%.Mid-Con Energy Partners (MCEP) +18%.Galera Therapeutics (GRTX) +15%.Dunkin' Brands (DNKN) +15%.GeoVax Labs (GOVX) +14%.Selecta Biosciences (SELB) +13%.Losers: BioSig
Seekingalpha · 10/26 16:38
Lianluo Smart, Galera Therapeutics leads healthcare gainers; BioSig Technologies, Aileron Therapeutics among major losers
Gainers: Lianluo Smart LLIT +30%, Galera Therapeutics GRTX +18%, Selecta Biosciences (SELB) +16%, Mirati Therapeutics MRTX +14%, GeoVax Labs GOVX +14%.Losers: BioSig Technologies BSGM -40%, Aileron Therapeutics ALRN -30%, BiondVax Pharmaceuticals (BVXV) -21%, Revolution Medicines RVMD -20%, ProPhase Labs (PRPH) -15%.
Seekingalpha · 10/26 15:03
Mid-Morning Market Update: Markets Open Lower; Hasbro Reports Upbeat Profit
Following the market opening Monday, the Dow traded down 1.33% to 27957.65 while the NASDAQ fell 0.17% to 11529.00. The S&P also fell, dropping 0.92% to 3,433.47.
Benzinga · 10/26 14:17
SAP, Cenovus Energy leads premarket losers' pack
BioSig Technologies (BSGM) -42% after announcing halt of its Phase 2 hospitalized COVID-19 trial.SAP (SAP) -21% on Q3 earnings release.Staffing 360 Solutions (STAF) -17%.Remark Holdings (MARK) -13%.Ever-Glory International Group (EVK) -14%.Contango Oil & Gas (MCF) -13% after
Seekingalpha · 10/26 12:34
Mid-Afternoon Market Update: Boston Beer Jumps On Upbeat Results; Limelight Networks Shares Plummet
Following the market opening Friday, the Dow traded down 0.21% to 28,303.91 while the NASDAQ rose 0.05% to 11,511.30. The S&P also rose, gaining 0.15% to 3,458.57.
Benzinga · 10/23 19:46
ADAP, LLNW, USX and TC among midday movers
Gainers: Socket Mobile (SCKT) +95%.Zedge (ZDGE) +42%.Marin Software Incorporated (MRIN) +37%.Dogness (International) (DOGZ) +35%.Strattec Security Corporation (STRT) +27%.Ever-Glory International Group (EVK) +24%.SenesTech (SNES) +18%.Recon Technology (RCON) +16%.Impac Mortgage Holdings (IMH) +17%.Adaptimmune
Seekingalpha · 10/23 16:38
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BVXV. Analyze the recent business situations of BiondVax through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BVXV stock price target is 81.00 with a high estimate of 81.00 and a low estimate of 81.00.
EPS
Institutional Holdings
Institutions: 26
Institutional Holdings: 503.92K
% Owned: 4.37%
Shares Outstanding: 11.52M
TypeInstitutionsShares
Increased
3
47.32K
New
14
4.86K
Decreased
4
11.78K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.01%
Pharmaceuticals & Medical Research
+0.65%
Key Executives
Chairman/Director
Mark Germain
Chief Executive Officer/President/Director
Ron Babecoff
Chief Financial Officer
Uri Ben-Or
Chief Scientific Officer
Tamar Ben-Yedidia
Other
Yisrael Gewirtz
Director
George Lowell
Director
Yael Margolin
Director
Samuel Moed
Director
Adi Raviv
Director
Jack Rosen
Director
Avner Rotman
Non-Executive Director
Irit Ben-Ami
Independent Director
Ruth Ben Yakar
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About BVXV
BiondVax Pharmaceuticals Ltd is an Israel-based is Phase 3 clinical phase biopharmaceutical company. It is developing the M-001 Universal Flu Vaccine. M-001 is undergoing a pivotal, clinical efficacy, Phase 3 trial in about 12,400 participants. M-001 is designed to provide multi-season and multi-strain protection against all human influenza virus strains, both seasonal and pandemic. In 6 completed clinical trials the vaccine was shown to be safe, well tolerated and immunogenic to a broad range of flu strains. The Company’s technology utilizes a proprietary combination of conserved and common peptides from influenza virus proteins to activate both arms of the immune system for a cross-protecting and long-lasting effect.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Biondvax Pharmaceuticals Ltd - ADR stock information, including NASDAQ:BVXV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BVXV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BVXV stock methods without spending real money on the virtual paper trading platform.